Summary
Introduction
It has been known for more than 20 years that embryonie stern cells can differentiate in vitro into various tissues of the endoderm, ectoderm and mesoderm. These cells can be maintained indefinitely in an undifferentiated state in the presence of leukaemia inhibiting factor (LIF, Williams et al., 1988) , and can be frozen and thawed without losing their pluripotent character. Upon removal of LIF from the culture, the cells grow and differentiate into various tissues, including contracting cardiomyocytes (Doetschman et al., 1985; Rohwedel et al., 2001; Wobus et al., 1991 Wobus et al., , 2005 by the addition of test substances to the culture medium can be readily investigated. The degree of inhibition of the development of contracting cardiomyocytes could be used as a measure of potential embryotoxicity, and thus the potential of the test substance to cause malformations, in other words, it could be used to identify a potentially teratogenic substance.
Embryonie stern cell tests using mouse cells (ESTs) were developed independently by Newall et al. (1994) and later by Spielmann et al. (1997) . They investigated the effects of various ehernieals on the viability of embryonie stern (ES) cells and differentiated adult fibroblast cells, as in an earlier study by Laschinsky et al. (1991) , as well as their effects on the ability of ES cells to differentiate into contracting cardiomyocytes. Three endpoints were determined: 50% inhibition of growth of both ES cells and fibroblasts, and 50% inhibition of differentiation into cardiomyocytes. The EST continued to be developed further and in 1997, Spielmann et al. investigated 16 chemieals with known in vivo embryotoxic potential. As part of the investigation, biostatistical models were developed to predict the in vivo embryotoxic potential of the test chemieals by classification into 3 different classes: non-, weakly, and strongly embryotoxic. The predictions of embryotoxicity obtained from the ESTs were compared to the in vivo results and agreed in all cases.
Since then the EST has been refined (Seiler et al., 2004 (Seiler et al., , 2006 ) and prediction models have been further developed to estimate toxic levels of chemieals in m.....
The EST, along with the whole embryo culture assay and the limb bud micromass assay, have been validated in an extensive study sponsored by ECVAM, the European Centre for the Validation of Alternative Methods (Scholz et al., 1999b; Genschow et al., 2000 Genschow et al., , 2002 Genschow et al., and 2004 . The EST assays resulted in an initial set of 6 chemieals being 93% correctly elassified, and 78% of the 14 chemie als were correctly elassified in the formal validation study.
This paper describes the use of the EST for pharmaceutical substances by studying 16 compounds, of which 10 were pharmaceutical substances developed by F. Hoffmann-La Roche AG and 6 had been tested already in the ECVAM validation study (Genschow et al., 2000 (Genschow et al., , 2002 (Genschow et al., , 2004 . Although only a limited number of compounds was investigated, the accuracy of the model predictions was sufficiently encouraging to warrant further development of the model to improve its database. An accurate and reliable prediction model would allow the screening of substances to give a ranking of the degree of embryotoxicity early in compound development. The EST could help to reduce animal experiments by replacing the in vivo screening model used in some laboratories.
Materials and methods

Test chemieals
Six chemieals were selected from the EC-VAM list on the basis of their embryotoxicity and reliable results from in vivo investigations. They ineluded two strongly (5-bromo-2-deoxyuridine, alltrans-retinoic acid), two weakly (lithium chloride, boric acid) and two non-embryotoxic (penicillin G sodium salt, saccharin sodium hydrate) chemieals. The 10 pharmaceutical substances tested were developed by F. Hoffmann-La Roche AG and had also been tested extensively in vivo. The compounds were derived from different chemical elasses (e.g. piperidine, pyridine, cyclic peroxide type) and were developed against different targets. Of these, five were strongly embryotoxic: Rl -an antimalarial substance which caused higher levels of intrauterine deaths in rats and rabbits, and blood 4 vessel and bone development anomalies in the rat.
R2 -an analgesie which induced oral elefts and an increased rate of intrauterine deaths. R3 -a collagen ase inhibitor which caused an increased incidence of intrauterine deaths, and severe craniofacial, cardiovascular and urogenital malformations. R4 -an oxidosqualene cyelase inhibitor which is embryolethal, causing a high level of intrauterine death and incidences of eleft palate. R5 -an oxidosqualene cyelase inhibitor causing malformations ineluding eleft palate.
Four substances were elassified as being non-embryotoxic: R6 -an inhibitor of monamine oxidase B. R7 -an oral cephalosporin, which was maternally toxic, but not embryotoxic. R8 -an analgesie and an enantiomer of R2. R9 -an ACE-inhibitor.
The remaining substance was weakly embryotoxic; it was the only one that had been so elassified in the in vivo experiments: RIO -a calcium antagonist which caused cardiovascular anomalies.
Cell culture
The two types of cells, Balb/c 3T3 cells (adult mouse fibroblast cells), elone A31, and embryonie stern cells (mouse), D3, were obtained from the American Type Culture Collection (ATCC), and were cultured by the method developed by Williams et al. (1988) . The fibroblast medium was DMEM (Gibco) supplemented with 10% FCS (Sigma), 4 mM glutamine, 50 Uzrnl penicillin, and 50 ug/ml streptomycin (the latter three from Gibco). ES cells were cultured by the same method, but using DMEM supplemented with 20% FCS, 2 mM glutamine, 50 Dlml penicillin, 50 ug/ml streptomycin, 1% non-essential amino acids (all from Gibco), 0.1 mM ß-mercaptoethanol (Sigma), and 1000 Dlml leukaemia inhibitory factor (Sigma), which was added directly to the plates. All cells were detached using 0.5% trypsinlEDTA (Gibco), counted and resuspended in culture medium three times per week.
Assays
The assay methods were those developed by Spielmann et al. 1997 and updated in INVITTOX, protocol no. 113 (1999) . All tests on the chemie als were carried out "blind". 
Biostatistical analysis and prediction model
Contingency tables
Contingency tables were developed by Genschow et al. (2002) Tables 2  and 3 . Representative figures illustrating concentration response curves of a nonembryotoxic compound (R9) are shown in Figure 1 and Figure 2 . All of the non-embryotoxic substances were correctly identified, thus giving 100% precision (Tab. 3).
In this work, the EST and the developed prediction model produced an accuracy of 81% (Tab. 3). When evaluated in terms of the performance of the elassification system developed by Genschow et al. (2002) , this result would be regarded as "good" and a strong basis for the screening of pharmaceutical substances early in their development.
One of the three weakly embryotoxic substances was falsely classified as being strongly embryotoxic, leading to a precision of 66.7% (Tab. 3). RIO is a calcium antagonist, which caused anomalies in the heart and blood vessels. Its effect in vivo on the cardiovascular system suggests that the differentiation of embryonie stern cells into beating cardiomyocytes could be heavily impaired. It was evident from the endpoint values that the effect was indeed much greater in the differentiation assay than on the viability of the D3 and 3T3 cells in the cytotoxicity assay, and this effect was sufficient to place the substance in a stronger elass of embryotoxicity.
Five out of seven strongly embryotoxic substances were correctly identified, giving aprecision of 71% (Tab. 3). Of the substances that were falsely elassified, R2 is an enantiomer of R8, which was correctly elassified in vitro. Both are analgesics. R2 caused eleft palate and resorptions in vivo. It had a elear effect on the inhibition of differentiation, but little effect on cell viability, thus elassifying it overall as being weakly instead of strongly embryotoxic. In agreement with Scholz et al. (I999a) , some substances that have no effect on the development of the heart could be correctly identified, but other treatments which affect particular tissues, ineluding the nervous system or the palate, may not be detected.
The second falsely classified substance, R3 (a collagenase inhibitor), showed little difference between the endpoints of differentiation and cytotoxicity. This substance was found to cause severe craniofacial, cardiovascular and urogenital malformations in vivo. However, the effect on the cells was not significant and both D3 and 3T3 cells were equally affected. It may be that the compound requires metabolie activations,
Results and discussion
The EST with the prediction model developed by ECVAM has proven to have potential as a screening tool for chemieals. Pharmaceutical substances tend to be more biologically active than chemieals and therefore the suitability the EST to detect the embryotoxic potential of these substances was investigated.
All 6 chemieals tested previously and 7 of the 10 pharmaceutical substances produced by F. Hoffmann-La Roche AG were elassified correct1y. In addition, the R9 ceneenn enon response curve m....
whieh was not taken into eonsideration in these assays. The EST has been developed using chemieals whieh require no metabolie proeessing to have effeets. However, some in vitro experiments have been earried <;,JUt with the inclusion of a metabolie aetivation system. Both Oglesby et al. (1986) and Piersma et al. (1991) added hepatoeytes to the whole embryo eulture system to test for embryotoxieity. It is known that thalidomide has little effeet on eytotoxieity (Moreira et al., 1999) but in the presenee of liver mierosomes an anti-angiogenie effeet is observed (Bauer et al., 1998; Sauer et al., 2000) . Conversely, metabolie aetivation may reduee the toxie effeet of substanees (Piersma, 2004) . Metabolie aetivation is yet to be explored extensively in the EST.
Typieal patterns eould often be found in the concentration-response eurves. Strongly embryotoxie substanees eaused inhibition of growth and differentiation at low eoneentrations. Weakly and nonembryotoxie substanees showed toxieity only at higher eoneentrations, whereby the differentiation potential tended to be the most strongly affeeted when substanees that were weakly embryotoxie were tested; the eytotoxieity of 3T3 cells Tab. 2: Contingency  table comparing in vive and in vitro classifications tended to be most affeeted when nonembryotoxie substanees were tested (Scholz et al., 1999a; Gensehow et al., 2002) . A balaneed eombination of the end points of the eytotoxieity test with undifferentiated and differentiated cells and the differentiation assay is known to give the most accurate results (Scholz et al., 1999b) . In eomparison to the ECVAM experiments, our results (aeeuraey of 81%) are a slight improvement on the predietion model used in the ECVAM study, whieh resulted in an aeeuraey of 78% (also classified as being "good") (Gensehow et al., 2004) . As already mentioned, an of those chemieals were known to re-
Conclusionsand outlook
The EST can be carried out rapidly and is cheap. It is a true in vitro test using wellestablished cell lines, thus completely avoiding the use of animals. It was shown that the .test is useful in the pharmaceutical industry as a screening tool very early in the development of substances to detect strongly embryotoxic substances and to remove them from further in vivo teratology testing. This would reduce the number of animals needed in embryotoxicity testing.
Further work has to be done to include a metabolic activation system and to increase the throughput of the assay. In addition, the potential use of the human embryonie stern cells that are now available should be explored.
